These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17673816)

  • 1. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
    Avilés A; Nambo MJ; Neri N; Cleto S; Castañeda C; Huerta-Guzmàn J; Murillo E; Contreras M; Talavera A; González M
    Med Oncol; 2007; 24(1):85-9. PubMed ID: 17673816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.
    Li Y; Yimamu M; Wang X; Zhang X; Mao M; Fu L; Aisimitula A; Nie Y; Huang Q
    Int J Hematol; 2014 Jan; 99(1):79-86. PubMed ID: 24258714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
    Avilés A; Calva A; Díaz-Maqueo JC; Talavera A; Huerta-Guzmán J; Vásquez E
    Leuk Lymphoma; 1997 Apr; 25(3-4):319-25. PubMed ID: 9168442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
    Economopoulos T; Psyrri A; Dimopoulos MA; Kalogera-Fountzila A; Pavlidis N; Tsatalas C; Nikolaides C; Mellou S; Xiros N; Fountzilas G
    Cancer J; 2007; 13(5):327-34. PubMed ID: 17921732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
    Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
    Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
    Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
    Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
    Murawski N; Pfreundschuh M; Zeynalova S; Poeschel V; Hänel M; Held G; Schmitz N; Viardot A; Schmidt C; Hallek M; Witzens-Harig M; Trümper L; Rixecker T; Zwick C
    Ann Oncol; 2014 Sep; 25(9):1800-1806. PubMed ID: 24928834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
    Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
    Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab and dose-dense chemotherapy in primary testicular lymphoma.
    Avilés A; Nambo MJ; Cleto S; Neri N; Huerta-Guzmán J
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):386-9. PubMed ID: 19858059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
    Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial.
    Avilés A; Nambo MJ; Castañeda C; Cleto S; Neri N; Murillo E; Huerta-Guzmán J; Contreras M
    Cancer Biother Radiopharm; 2007 Apr; 22(2):194-9. PubMed ID: 17600466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.